Literatura ACTA MEDICINAE 4/2018 Kazuistiky v onkologii a hematoonkologii

Transkript

1 Literatura 2 Pacientka s karcinomem prsu a Darierovou nemocí, léčená adjuvantní radioterapií doc. MUDr. Josef Dvořák, Ph.D. MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha 2 Léčba metastatického HER2 pozitivního karcinomu prsu MUDr. Lucie Reifová Ústav radiační onkologie, Nemocnice Na Bulovce, Praha 2 Léčba PARP inhibitory MUDr. Mária Zvaríková Klinika komplexní onkologické péče, MOÚ, Brno 2 Využití bevacizumabu v léčbě metastatického karcinomu děložního hrdla MUDr. Anna Germanová, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha 2 Karcinom pankreatu MUDr. Lenka Ostřížková Interní, hematologická a onkologická klinika LF MU a FN Brno 3 Účinnost sunitinibu v režimu dávkování v první linii léčby metastatického karcinomu ledviny MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u svaté Anny v Brně MUDr. Petr Filipenský Urologické oddělení, FN u svaté Anny v Brně MUDr. Jiří Vaníček, Ph.D. Klinika zobrazovacích metod, FN u svaté Anny v Brně 3 Účinnost axitinibu u nemocného v léčbě druhé linie metastazujícího karcinomu ledviny doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 3 Dobrý efekt bevacizumabu v léčbě u pacientů s NSCLC MUDr. Michaela Pařezová Klinika nemocí plicních a TBC, FN Brno MUDr. Lenka Jakubíková, Ph.D. prof. MUDr. Jana Skřičková, CSc. Klinika nemocí plicních a TBC FN a LF MU, Brno 3 Mohou tyrosinkinázové inhibitory ovlivnit mozkové metastázy? MUDr. Libor Havel Pneumologická klinika 1. LF UK Praha, Thomayerova nemocnice Praha 4 Kompletní odpověď primárního tumoru a regionální lymfadenopatie po léčbě panitumumabem pacientky s generalizovaným adenokarcinomem rekta doc. MUDr. Josef Dvořák, Ph.D. MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha 4 Léčba idelalisibem jako bridge therapy k alogenní transplantaci krvetvorných buněk u nemocného s vysoce rizikovou chronickou lymfocytární leukemií MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové 4 Nivolumab a brentuximab vedotin jako efektivní terapie pacienta s relabujícím/refrakterním Hodgkinovým lymfomem před alogenní transplantací hemopoetických kmenových buněk MUDr. Jozef Michalka Interní hematologická a onkologická klinika FN Brno a LF MU, Brno 4 Dasatinib v léčbě chronické myeloidní leukemie s těžkou jaterní toxicitou předchozí léčby imatinibem MUDr. Daniela Žáčková, Ph.D. Interní, hematologická a onkologická klinika LF MU a FN Brno 5 Obinutuzumab a bendamustin léčba relabujícího folikulárního lymfomu MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK Praha 5 Léčba staršího pacienta s B-CLL kombinací obinutuzumabu s chlorambucilem MUDr. Petr Kessler Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov 5 Recidivujúce respiračné infekcie u pacienta s refraktérnou chronickou lymfocytovou leukémiou liečeného ibrutinibom MUDr. Ľudmila Demitrovičová, Ph.D. Oddelenie onkohematológie II., Národný onkologický ústav, Bratislava

2 Pacientka s karcinomem prsu a Darierovou nemocí, léčená adjuvantní radioterapií doc. MUDr. Josef Dvořák, Ph.D. MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha 1 Burkoň, P. Čoupek, P. Princ, D., et al.: Zhoubné nádory prsu. In: Šlampa, P., et al.: Radiační onkologie v praxi, 2014, 4, s Masarykův onkologický ústav, Brno. 2 Takagi, A. Kamijo, M. Ikeda, S.: Darier disease. J Dermatol, 2016, 43, s Suryawanshi, H. Dhobley, A. Sharma, A., et al.: Darier disease: A rare genodermatosis. J Oral Maxillofac Pathol, 2017, 21, s. 321, doi: /jomfp.JOMFP_170_16. 4 Podgornii, A. Ciammella, P. Ramundo, D. Iotti, C.: Efficacy of the radiotherapy on Darier s disease: an indirect evidence. Case Rep Dermatol Med, 2013, 2013, s Mac Manus, M. P. Cavalleri, G. Ball, D. L., et al.: Exacerbation, then clearance, of mutation-proven Darier s disease of the skin after radiotherapy for bronchial carcinoma: a case of radiation-induced epidermal differentiation? Radiat Res, 2001, 156, s Léčba metastatického HER2 pozitivního karcinomu prsu MUDr. Lucie Reifová Ústav radiační onkologie, Nemocnice Na Bulovce, Praha 1 Slamon, D. J. Leyland-Jones, B. Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344, s Baselga, J. Cortés, J. Kim, S.-B., et al.; CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastaic breast cancer. N Engl J Med, 2012, 366, s Adams, C. W. Allison, D. E. Flagella, K., et al.: Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother, 2006, 55, s Barok, M. Joensuu, H. Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistence. Breast Cancer Research, 2014, 16, s. 209, dostupné z: vyhledáno Cardoso, F. Harbeck, N. Fallowfield, L., et al.: Locally recurent or metastatic breast cancer: ESMO Practice Guidelines for diagnosis, treat ment and follow up. Ann Oncol, 2012, 23, suppl. 7, s. vii Vyzula, R., et al.: Modrá kniha ČOS. Brno, 22. aktualizace, platnost od ; Zhoubný novotvar prsu, kapitola Biologická léčba, pertuzumab indikace. 7 Swain, S. M. Kim, S. B. Cortés, J., et al.: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 2013, 14, s Balduzzi, S. Mantarro, S. Guarneri, V., et al.: Trastuzumab containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, 2014, 6, CD006242, doi: / CD pub2. 9 Cortes, J. Baselga, J. Im, Y. H., et al.: Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol, 2013, 24, s Léčba PARP inhibitory MUDr. Mária Zvaríková Klinika komplexní onkologické péče, MOÚ, Brno 1 Valerie, K. Povirk, L. F.: Regulation and mechanisms of mammalian double-strand break repair. Oncogene, 2003, 22, s Sung, P. Klein, H.: Mechanism of homolog sousre combination: mediators and helicasestake on regulatory functions. Nat Rev Mol Cell Biol, 2006, 7, s Krejci, L. Altmannova, V. Spirek, M. Zhao, X.: Homologous recombination and its regulation. Nucleic Acids Res, 2012, 40, s d Adda di Fagagna, F. Hande, M. P. Tong, W. M., et al.: Functions of poly(adp-ribose) polymerase in controlling telomere length and chromosomal stability. Nat Genet, 1999, 23, s Tong, W. M. Cortes, U. Wang, Z. Q.: Poly (ADP-ribose) polymerase: a guardianan gel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta, 2001, 1552, s Helleday, T. Petermann, E. Lundin, C., et al.: DNA repair path ways as targets for cancer therapy. Nat Rev Cancer, 2008, 8, s Weil, M. K. Chen, A. P.: PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer, 2011, 35, s Ledermann, J. Harter, P. Gourley, C., et al.: Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving Olaparib maintenance monotherapy: anup dated analysis from a randomized, placebo controlled double blind, phase 2 trial. Lancet Oncol, 2016, 17, s Matulonis, U. Harter, P. Gourley, C., et al.: Olaparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and BRCA mutation: overall survival adjusted for postprogression poly (adenosinediphosphate ribose) polymerase inhibitor therapy. Cancer, 2016, 122, s Moore, K. DiSilvestro, P. Lowe, E., et al.: SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). J Clin Oncol, 2014, 32, abstrakt TPS5616. Využití bevacizumabu v léčbě metastatického karcinomu děložního hrdla MUDr. Anna Germanová, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha 1 Ngo, O. Májek, O. Krejčí, D. Mužík, J., et al.: Epidemiologie zhoubných nádorů děložního hrdla v České republice. Gynekologie a porodnictví, 2017, 5, s Penson, R. T. Huang, H. Q. Wenzel, L. B., et al.: Patient reported outcomes in practise changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study. Lancet Oncol, 2015, 16, s Poolkerd, S. Leelakahorn, S. Manusirivithaya, S., et al.: Survival rate of recurrent cervical cancer patients. J Med Assoc Thai, 2006, 89, s Gaducci, A. Tana, R. Coscio, S., et al.: Treatment options in recurrent cervical cancer (Review). Oncol Lett, 2010, 1, s Minion, L. E. Tewari, K. S.: Cervical cancer state of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol, 2018, 148, s Karcinom pankreatu MUDr. Lenka Ostřížková Interní, hematologická a onkologická klinika LF MU a FN Brno 1 Buchs, N. C. Chilcott, M. Poletti, P. A., et al.: Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol, 2010, 16, s Oettle, H. Post, S. Neuhaus, P., et al.: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative- -intentresection of pancreatic cancer: a randomized controlled trial. JAMA, 2007, 297, s Von Hoff, D. D. Ramanathan, R. K. Borad, M. J., et al.: Gemcitabine plus nab-paclitaxelis an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J ClinOncol, 2011, 29, s doi: /JCO , Epub

3 Účinnost sunitinibu v režimu dávkování v první linii léčby metastatického karcinomu ledviny MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u svaté Anny v Brně MUDr. Petr Filipenský Urologické oddělení, FN u svaté Anny v Brně MUDr. Jiří Vaníček, Ph.D. Klinika zobrazovacích metod, FN u svaté Anny v Brně 1 Motzer, R. Hutson, T. Tomczak, P., et al.: Sunitinib versus interferon alfa in metastaticrenal-cell carcinoma. N Engl J Med, 2007, 356, s Rini, B. I. Cohen, D. P. Lu, D. R., et al.: Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal carcinoma (mrcc) treated with sunitinib ASCO Genitourinary Cancers Symposium, abstrakt Michaelson, M. D. Cohen, D. P. Li, S., et al.: Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal carcinoma (mrcc) treated with sunitinib (SU) ASCO Genitourinary Cancer Symposium, abstrakt Schmid, T. A. Gore, M. E.: Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol, 2016, 8, s Lee, J. Kim, M. Park, I. Ahn, J., et al.: Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Ann Oncol, 2015, 26, s Účinnost axitinibu u nemocného v léčbě druhé linie metastazujícího karcinomu ledviny doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 1 Lakomy, R. Poprach, A. Bortlicek, Z., et al.: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer, 2017, 17, s. 880, doi: /s Wells, J. C. Stukalin, I. Norton, C., et al.: Third-line targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 2017, 71, s Motzer, R. J. Escudier, B. Oudard, S., et al.: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 2010, 116, s Rini, B. I. Escudier, B. Tomczak, P., et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, 2011, 378, s Motzer, R. J. Escudier, B. McDermott, D. F., et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med, 2015, 373, s Choueiri, T. K. Escudier, B. Powles, T., et al.; METEOR investigators: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol, 2016, 17, s Motzer, R. J. Hutson, T. E. Glen, H., et al.: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol, 2015, 16, s Melichar, B. Poprach, A. Kubáčková, K., et al.: Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mrcc): Comparison of Czech clinical registry and AXIS trial data. European Cancer Congress 2015, abstrakt Dobrý efekt bevacizumabu v léčbě u pacientů s NSCLC MUDr. Michaela Pařezová Klinika nemocí plicních a TBC, FN Brno MUDr. Lenka Jakubíková, Ph.D. prof. MUDr. Jana Skřičková, CSc. Klinika nemocí plicních a TBC FN a LF MU, Brno 1 Sandler, A. Gray, R. Perry, M. C., et al.: Paclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancer M.D.N Engl J Med, 2006, 355, s Reck, M. von Pawel, J. Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabin with ether placebo or bevacizumab as first-line therapy for non-small-cell lung cancer: AVAil. J Clin Oncol, 2009, 27, s Adam, Z. Vorlíček, J., et al.: Speciální onkologie. Brno, Masarykova univerzita, Dušek, L. Májek, O. Krejčí, D., et al.: Epidemiologie zhoubných nádorů plic, průdušnice a průdušek v ČR. In: Skřičková, J. Kolek, V., et al.: Základy moderní pneumoonkologie. 2017, Maxdorf, Praha, s SPC přípravku Avastin. 6 Dostupné z: vyhledáno Mohou tyrosinkinázové inhibitory ovlivnit mozkové metastázy? MUDr. Libor Havel Pneumologická klinika 1. LF UK Praha, Thomayerova nemocnice Praha 1 Jemal, A. Bray, F. Center, M. M., et al.: Global cancer statistics. CA Cancer J Clin, 2011, 61, s /caac Schuette, W.: Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer, 2004, 45, suppl. 2, s /j. lungcan Langer, C. J. Mehta, M. P.: Current management of brain metastases, with a focus on systemicoptions. J Clin Oncol, 2005, 23, s /jco Lagerwaard, F. J. Levendag, P. C. Nowak, P. J., et al.: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys, 1999, 43, s / S (98) Han, G., et al.: A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget, 2016, 7, s Stanic, K., et al.: Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol, 2014, 48, s Rangachari, D., et al.: Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer, 2015, 88, s Luo, D. Ye, X. Hu, Z., et al.: EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol, 2014, 35, s /s Jackman, D. M.: A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget, 2015, 6, s Katayama, T.: Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma whos how edinitial good response to gefitinib. J Thorac Oncol, 2009, 4, s Clarke, J. L.: High dose weekly erlotinib achieves therapeutic concentrations in CSF and iseffective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol, 2010, 99, s Grommes, C.: Pulsatile high-dose weekly erlotinibfor CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol, 2011, 13, s The ASCO Post: Afatinib Shows Clinical Benefit for Non Small Cell Lung Cancer Patients With Brain Metastases. Posted: 2/1/ Ballard, P. Yates, J. W. Yang, Z., et al.: Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res, 2016, 22, s Goss, G. Tsai, C. M. Shepherd, F. A., et al.: CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials. Prezentováno na World Congress on Lung Cancer, Vídeň, Rakousko, J Thorac Oncol, 2017, 12, s. S226, MA Mok, T. S., et al.: CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). J Clin Oncol, 2017, 35, suppl., s Soria, J. C., et al.: Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N Engl J Med, 2018, 378, s Mok, T., et al.: Prezentováno na ASCO Annueal Meering , Chicago, USA. J Clin Oncol, 2017, 36, suppl., abstrakt Vansteenkiste, J., et al.: CNS response to osimertinib vs. standard-of- -care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA. Prezentováno na European Society of Medical Oncology (ESMO) Asia 2017 Congress, , Singapur. 20 Mok,T. S., et al.: Osimertinib or platinum pemetrexed in EGFR T790M positive lung cancer. N Engl J Med, 2017, 376, s

4 Kompletní odpověď primárního tumoru a regionální lymfadenopatie po léčbě panitumumabem pacientky s generalizovaným adenokarcinomem rekta doc. MUDr. Josef Dvořák, Ph.D. MUDr. Aneta Rozsypalová Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha MUDr. Radek Zapletal Onkologická klinika 1. LF UK a Thomayerova Nemocnice, Praha 1 Dušek, L. Pavlík, T. Májek, O., et al.: Odhady incidence, prevalence a počtu onkologických pacientů léčených protinádorovou terapií v letech 2015 a 2020 analýza Národního onkologického registru ČR. Klinická onkologie, 2015, 28, s Douillard, J. Y. Siena, S. Cassidy, J., et al.: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously un treated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010, 28, s Schwartzberg, L. S. Rivera, F. Karthaus, M., et al.: PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mfolfox6) or bevacizumab plus mfolfox6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol, 2014, 32, s Tomášek, J. Mokrá, L. Bortlíček, Z.: Panitumumab v 1. linii léčby metastatického kolorektálního karcinomu výsledky v běžné praxi lepší než v registrační studii. Farmakoterapie, 2016, 12, s Richter, I. Dvořák, J. Bartoš, J., et al.: Aktuální možnosti chemoradioterapie lokálně pokročilého karcinomu rekta. Onkologie, 2015, 9, s Léčba idelalisibem jako bridge therapy k alogenní transplantaci krvetvorných buněk u nemocného s vysoce rizikovou chronickou lymfocytární leukemií MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové 1 Dreger, P. Corradini, P. Kimby, E., et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia, 2007, 21, s Dreger, P. Dohner, H. Ritgen, M., et al.: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 2010, 116, s Khouri, I. F. Bassett, R. Poindexter, N., et al.: Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer, 2011, 117, s Furman, R. R. Sharman, J. P. Coutre, S. E., et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New Eng J Med, 2014, 370, s Dreger, P. Schetelig, J. Andersen, N., et al.: Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood, 2014, 124, s Hallek, M. Cheson, B. D. Catovsky, D., et al.: Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood, 2018, publikováno online před tiskem. Nivolumab a brentuximab vedotin jako efektivní terapie pacienta s relabujícím/refrakterním Hodgkinovým lymfomem před alogenní transplantací hemopoetických kmenových buněk MUDr. Jozef Michalka Interní hematologická a onkologická klinika FN Brno a LF MU, Brno 1 Swerdlow, S. H. Campo, E. Harris, N. L., et al.: WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, Küppers, R. Rajewsky, K.: The origin of Hodgkin and Reed/ Sternberg cells in Hodgkin s disease. Annu Rev Immunol, 1998, 16, s Roemer, M. G. Advani, R. H. Ligon, A. H., et al.: PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol, 2016, 34, s Freeman, G. J. Long, A. J. Iwai, Y., et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 2000, 192, s Yamamoto, R. Nishikori, M. Kitawaki, T., et al.: PD-1 PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood, 2008, 111, s Schmitz, N. Pfistner, B. Sextro, M., et al.: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin s disease: a randomised trial. Lancet, 2002, 359, s Moskowitz, C. H. Nademanee, A. Masszi, T., et al.: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet (London, England), 2015, 385, s Arai, S. Fanale, M. DeVos, S., et al.: Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma, 2013, 54, s Younes, A. Gopal, A. K. Smith, S. E., et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin s lymphoma. J Clin Oncol, 2012, 30, s Chen, R. Gopal, A. K. Smith, S. E., et al.: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Publikováno , doi: / blood Armand, P.: Immune checkpoint blockade in hematologic malignancies. Blood, 2015, 125, s Ansell, S. M. Lesokhin, A. M. Borrello, I., et al.: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin s lymphoma. N Engl J Med, 2015, 372, s Younes, A. Santoro, A. Shipp, M.: Nivolumab for classical Hodgkin s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol, 2016, 17, s Timmerman, J. M. Engert, A. Younes, A., et al.: Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood, 2016, 128, s Cheson, B. D. Ansell, S. Schwartz, L., et al.: Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood, 2016, 128, s Chen, R. Palmer, J. M. Popplewell, L., et al.: Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol, 2011, 90, s Sureda, A. Robinson, S. Canals, C., et al.: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol, 2008, 26, s Perales, M. A. Ceberio, I. Armand, P., et al.: American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant, 2015, 21, s Merryman, R. W. Kim, H. T. Zinzani, P. L., et al.: Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 2017, 129, s Dasatinib v léčbě chronické myeloidní leukemie s těžkou jaterní toxicitou předchozí léčby imatinibem MUDr. Daniela Žáčková, Ph.D. Interní, hematologická a onkologická klinika LF MU a FN Brno 1 Druker, B. J. Guilhot, F. O Brien, S. G., et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355, s Cohen, M. H. Williams, G. Johnson, J. R., et al.: Approval summary for imatinib mesylateca psules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 2002, 8, s Dostupné z: CAE_4.03_ _QuickReference_5x7.pdf, vyhledáno Talpaz, M. Silver, R. T. Druker, B. J., et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: resultsof a phase 2 study. Blood, 2002, 99, s Cross, T. J. Bagot, C. Portmann, B., et al.: Imatinib mesylate as a cause of acute liver failure. Am J Hematol, 2006, 81, s Ridruejo, E. Cacchione, R. Villamil, A. G., et al.: Imatinib-induced fatalacute liver failure. World J Gastroenterol, 2007, 13, s Thia, T. J. Tan, H. H. Chuah, T. H., et al.: Imatinib mesylate-related fatalacute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J, 2008, 49, s Perini, G. F. Santos, F. P. Funke, V., et al.: Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. Leuk Res, 2009, 33, s Martínez Pascual, C. Valdés Mas, M. de la Peña Moral, J. M., et al.: Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia. Med Clin (Barc), 2011, 137, s Harding, D. J. MacQuillan G. Howman, R., et al.: Successful use of

5 dasatinib after liver transplantation for imatinib-induced fulminant liver failure in chronic myeloid leukemia. J Clin Oncol, 2016, 34, s Nacif, L. S. Waisberg, D. R. Pinheiro, R. S., et al.: Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. J Med Case Rep, 2018, 12, s Ohyashiki, K. Kuriyama, Y. Nakajima, A., et al.: Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia, 2002, 16, s Kong, J. H. Yoo, S. H. Lee, K. E., et al.: Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol, 2007, 118, s Ayoub, W. S. Geller, S. A. Tran, T., et al.: Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol, 2005, 39, s James, C. Trouette, H. Marit, G., et al.: Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia, 2003, 17, s Mindikoglu, A. L. Regev, A. Bejarano, P. A., et al.: Imatinib mesylate (gleevec) hepatotoxicity. Dig Dis Sci, 2007, 52, s Kikuchi, S. Muroi, K. Takahashi, S., et al.: Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its seru concentration with clinical outcomes. 2009, Leukemia Lymphoma, 45, s Spataro, V.: Nilotinib in a patient with post necrotic liver cirrhosis related toimatinib. J Clin Oncol, 2011, 29, s Ferrero, D. Pogliani, E. M. Rege-Cambrin, G., et al.: Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica, 2006, 91, 6, suppl., ECR Gupta, S. Bhatt, V. R. Varma, S.: Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient access fully managed with prednisone. BMJ Case Rep, 2011, /bcr Paech, F. Bouitbir, J. Krähenbühl, S.: Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front Pharmacol, 2017, 8, s Harbaum, L. Marx, A. Goekkurt, E., et al.: Treatment with dasatinib for chronic myeloid leukemia followin gimatinib-induced hepatotoxicity. Int J Hematol, 2014, 99, s Al Sobhi, E. Zahrani, Z. Zevallos, E., et al.: Imatinib-induced immune hepatitis: case report and literature review. Hematology, 2007, 12, s Ikuta, K. Torimoto, Y. Jimbo, J., et al.: Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisol one for its management. Int J Hematol, 2005, 82, s Yamazaki, R. Okamoto, S. Chen, C. K., et al.: Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leuk Lymphoma, 2006, 47, s Cortes, J. E. Hochhaus, A. lecoutre, P. D., et al.: Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronicorac celerated phase who are intolerant to imatinib. Blood, 2011, 117, s Hochhaus, A. Kantarjian, H. M. Baccarani, M., et al.: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 2007, 109, s Harding, D. J. MacQuillan, G. Howman, R., et al.: Successful use of dasatinib after liver transplantation for imatinib-induced fulminant liver failure in chronic myeloid leukemia. J Clin Oncol, 2016, 34, s Shah, R. R. Morganroth, J. Shah, D. R.: Hepatotoxicity of tyrosinekinase inhibitors: clinical and regulatory perspectives. Drug Saf, 2013, 36, s Tokarski, J. S. Newitt, J. A. Chang, C.Y., et al.: The structure of dasatinib (BMS ) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res, 2006, 66, s Dostupné z: pdf, vyhledáno Obinutuzumab a bendamustin léčba relabujícího folikulárního lymfomu MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK Praha 1 Link, B. K. Day, B. M. Zhou, X., et al.: Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol, , doi: /bjh.15149, Epub před tiskem. 2 Jurinovic, V. Metzner, B. Pfreundschuh, M., et al.: Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of two randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant, , pii: S (18) , doi: /j. bbmt , Epub před tiskem. 3 Cheson, B. D. Chua, N. Mayer, J., et al.: Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study. J Clin Oncol, , CO , doi: /JCO , Epub před tiskem. 4 Cheson, B. D. Trask, P.C. Gribben, J. G., et al.: Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Ann Hematol, 2017, 96, s Sehn, L. H. Chua, N. Mayer, J., et al.: Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol, 2016, 17, s Salles, G. A. Morschhauser, F. Solal-Celigny, P., et al.: Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol, 2013, 31, s Radford, J. Davies, A. Cartron, G., et al.: Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood, 2013, 122, s Léčba staršího pacienta s B-CLL kombinací obinutuzumabu s chlorambucilem MUDr. Petr Kessler Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov 1 Hillmen, P. Gribben, J. G. Follows, G. A., et al.: Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol, 2014, 32, s Gagez, A. L. Cartron, G.: Obinutuzumab: a new class of anti-cd20 monoclonal antibody. Curr Opin Oncol, 2014, 26, s Goede, V. Fischer, K. Busch, R., et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med, 2014, 370, s Freeman, C. L. Dixon, M. Houghton, R., et al.: Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia, 2016, 30, s Recidivujúce respiračné infekcie u pacienta s refraktérnou chronickou lymfocytovou leukémiou liečeného ibrutinibom MUDr. Ľudmila Demitrovičová, Ph.D. Oddelenie onkohematológie II., Národný onkologický ústav, Bratislava 1 SPC prípravku Imbruvica 140 mg capsules, Byrd, J. C. Coutre, S. E.: Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL recieving signgle-agent ibrutinib. Blood, 2015, 125, s Dubovsky, J. A. Beckwith, K. A. Natarajan, G.: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood, 2013, 122, s Sun, C. Tian, X. Lee, S.: Partial reconstitution of humoral imunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood, 2015, 126, s Demitrovicova, L. Mikuskova, E. Oravcova, I., et al.: Infectious complications in chronic lymphocytic leukemia a retrospective analysis: single institution experience. Neoplasma, 2017, 64, s